Puma Biotechnology to Discuss Q2 2024 Financial Results in Conference Call

Puma Biotechnology, Inc., a company specializing in biopharmaceuticals, is set to hold a conference call on Thursday, August 1, 2024, at 1:30 p.m. PDT/4:30 p.m. EDT. This call will be conducted after the release of its financial results for the second quarter of 2024. To join the call, participants should dial 1-877-709-8150 within the United States or 1-201-689-8354 for international callers at least ten minutes before the scheduled start time. The call is described as the “Puma Biotechnology Conference Call.” Additionally, a live webcast of the call, along with the presentation slides, will be available on Puma Biotechnology’s Investors section on its website. For those who cannot attend the live session, a replay will be accessible approximately one hour after the call’s conclusion and will remain available on the company’s website for 90 days.

Puma Biotechnology, Inc. is dedicated to the development and commercialization of innovative cancer treatments. One of their key products is PB272 (neratinib, oral), for which they acquired global development and commercialization rights in 2011. The oral form of neratinib was approved by the U.S. FDA in 2017 for extended adjuvant treatment of adult patients with early stage HER2-overexpressed or amplified breast cancer, following trastuzumab-based therapy. This product is marketed in the United States under the name NERLYNX® (neratinib) tablets. Additionally, in February 2020, the FDA approved NERLYNX in combination with capecitabine for treating adult patients with advanced or metastatic HER2-positive breast cancer, who have previously undergone two or more anti-HER2-based regimens in the metastatic setting. Moreover, in 2018, the European Commission authorized the marketing of NERLYNX for extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed or amplified breast cancer, who are within one year of completing prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc.

In September 2022, Puma Biotechnology entered into an exclusive licensing agreement for the anti-cancer drug alisertib. Alisertib is an investigational, selective, small molecule inhibitor of aurora kinase A, administered orally. Puma's initial focus for developing alisertib is on treating small cell lung cancer and breast cancer. By February 2024, Puma had begun a Phase II clinical trial named ALISCA™-Lung 1, which investigates the use of alisertib monotherapy for patients with extensive-stage small cell lung cancer.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!